Barcelona clinic study counts how many gay men might benefit from PrEP
Women living with HIV in the UK continue to have poorer treatment outcomes
Does low-level HIV viral load raise the risk of disease progression and co-morbidities?
Hepatitis C incidence remains stable among gay men living with HIV in Europe, but varies across countries
Priorities for HIV care: the perspectives of healthcare providers and patients
Sofosbuvir/ledipasvir for 8 weeks cures most hard-to-treat hepatitis C patients in real-world study
Successful hepatitis C treatment lowers risk of death for people with HIV and HCV co-infection
HIV maturation inhibitor BMS-955176 shows good safety and efficacy in phase 2a trial
START sub-studies show no differences in lung or neurocognitive function with early or later treatment
START sub-study shows more bone loss with earlier HIV treatment
London clinic survey shows impact of chemsex on condom and PEP use
Risk of heart attack rises with length of HIV infection, regardless of age
With EACS release, all international HIV treatment guidelines agree on when to start – for the first time since 2006
Tenofovir alafenamide single-tablet regimen shows good efficacy with improved kidney and bone safety
When will Europe get PrEP?
Can dolutegravir dual therapy or monotherapy produce and maintain HIV suppression?
The majority of migrants living with HIV in Europe may have acquired HIV in their new country
Benefits of early HIV treatment are clear, but issues raised by START and D:A:D remain unresolved
